Melbourne-based Phosphagenics (ASX:POH) -– formerly Vital Capital -– has flagged its intention to seek a dual listing on the London Stock Exchange's Alternative Investment Market (AIM). [ + ]

Researchers at Griffith University's Genomics Research Centre have found an important clue to the cause of hormonally induced migraines, that may explain why women are three times more likely than men to suffer from migraine. [ + ]

Queensland based veterinary plasma company PlasVacc has signed and agreement to supply CSL with horse plasma for anti-venom applications. [ + ]

A federal government decision earlier this month to stockpile Roche's Tamiflu, rather than the anti-flu drug Relenza, designed by Melbourne-based Biota (ASX:BTA), is being used by the Australian firm to support its legal claims that GlaxoSmithKline failed to support and promote Relenza. [ + ]

Sydney-based cryogenic storage company Cryosite (ASX: CTE) has entered into an agreement with Melbourne's Peter MacCallum Cancer Centre to provide long term storage of patients' blood stem cells. [ + ]

The spin-off and listing of BioPharmica was approved at a general meeting of Grandbridge (ASX: GBA) shareholders today by more than 99 per cent of shareholders. [ + ]

Australian and US defence interests have signed a $4.6 million contract to conduct a controlled scramjet experiment at Mach 10, or 10 times the speed of sound, at Woomera next year. UNSW at Australian Defence Force Academy is a partner in the project.

The President of the Australian Academy of Science, Dr Jim Peacock, has warned that governments could do “irreparable and lasting harm” by seeking to play safe when confronted by controversial technological change. [ + ]

Nanotechnology company pSivida's (ASX: PSD) UK subsidiary pSiMedica has signed a collaborative agreement with the University of Pittsburgh to evaluate the use of BioSilicon as a delivery platform for the university's proprietary DNA vaccine technology. [ + ]

The European Patent Office's decision to revoke a key patent on a breast cancer test owned by Utah-based Myriad Genetics will not prevent Myriad's Australian licensee, Genetic Technologies Ltd (ASX: GTG) providing the test in Australia and Asia. [ + ]

The Victorian State Government will fund another round of the Science Technology Innovation Infrastructure Grants program (STII), providing $60 million to supports biomedical, environmental, agricultural, manufacturing and ICT infrastructure projects. [ + ]

Australian Cancer Technologies (AustCancer, ASX: ACU) is the latest Australian company to announce an acquisition of a US company, with its proposal to acquire US vaccine developer Galenica Pharmaceuticals for around US$5 million in shares. [ + ]

The future of the Victorian wheat industry has moved from a biosecure glasshouse into a small, netted field plot at the International Centre for Cereal Breeding (CIMMYT) in Mexico. [ + ]

Almost two months ago, the Victorian Labor government stunned the state's biotechnology industry by imposing a four-year, legislated moratorium on genetically modified (GM) canola cropping. [ + ]

Cell therapeutics company Living Cell Technologies has issued a prospectus to raise almost AUD$7 million through both a rights issue and a general issue. [ + ]